Jounce Therapeutics, Inc. Common Stock
JNCE
JNCE was delisted on the 3rd of May, 2023.
80 hedge funds and large institutions have $153M invested in Jounce Therapeutics, Inc. Common Stock in 2019 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 25 increasing their positions, 30 reducing their positions, and 13 closing their positions.
88% more capital invested
Capital invested by funds: $81.8M → $153M (+$71.6M)
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
5% less funds holding
Funds holding: 84 → 80 (-4)
17% less repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 30
31% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Erste Asset Management
Vienna,
Austria
|
+$1.25M |
| 2 |
AQR Capital Management
Greenwich,
Connecticut
|
+$1.24M |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$1.11M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$914K |
| 5 |
Prudential Financial
Newark,
New Jersey
|
+$823K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$1.64M |
| 2 |
Two Sigma Investments
New York
|
-$999K |
| 3 |
Renaissance Technologies
New York
|
-$962K |
| 4 |
Millennium Management
New York
|
-$735K |
| 5 |
Morgan Stanley
New York
|
-$500K |
JNCE Hedge Fund Activity: Q1 2019 in Review
80 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Jounce Therapeutics, Inc. Common Stock (JNCE) for Q1 2019, worth a combined $153M — up 88% from $81.8M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of JNCE and 9 opened new positions — a net loss of 4 holders — while 30 trimmed existing stakes and 25 added.
The largest buyer was Erste Asset Management, adding an estimated $1.25M. The largest seller was JP Morgan Chase, cutting an estimated $1.64M.
- 80 institutional investors held Jounce Therapeutics, Inc. Common Stock (JNCE) as of Q1 2019, down from 84 in Q4 2018.
- Funds reported $153M of Jounce Therapeutics, Inc. Common Stock stock for Q1 2019, up 88% quarter-over-quarter.
- 9 funds opened new Jounce Therapeutics, Inc. Common Stock positions in Q1 2019 and 13 closed out, a net change of -4 holders.
- The largest Jounce Therapeutics, Inc. Common Stock buyer in Q1 2019 was Erste Asset Management, an estimated $1.25M added.
- The largest Jounce Therapeutics, Inc. Common Stock seller in Q1 2019 was JP Morgan Chase, an estimated $1.64M sold.
Based on aggregated 13F filings for Q1 2019.